Clomiphene Side Effects: What Studies Report
Published clomiphene research splits into two safety literatures. In women undergoing ovulation induction, a large PCOS trial reported hot flushes more often with clomiphene than letrozole, while fatigue and dizziness were more frequent with letrozole (PMID 25006718), and a randomized trial examined endometrial ultrastructure under clomiphene (PMID 32309769). In men studied off-label, meta-analyses reported testosterone increases with adverse events described as infrequent and generally mild (PMID 34933414, PMID 36680549). This page summarises what those papers reported, without recommending anything.
Where clomiphene appears in the published literature
Clomiphene citrate is a selective estrogen receptor modulator that has been examined in reproductive medicine for decades. The published safety literature falls into two fairly separate bodies of work. The first concerns women undergoing ovulation induction, where clomiphene has been compared directly against letrozole and against other interventions in randomized trials. The second concerns men, where a 2022 systematic review and meta-analysis described clomiphene citrate as an off-label option studied in men with hypogonadism and pooled the hormonal and safety outcomes reported by the included studies (PMID 34933414).
Because the two populations differ in age, sex, treatment duration and the outcomes investigators chose to record, adverse events reported in one setting do not transfer cleanly to the other. This page reports what each paper stated within its own population and does not extrapolate between them.
Reported Adverse Events in Ovulation Induction: What Studies Report
Vasomotor and general complaints
The most frequently cited comparison of tolerability comes from a multicentre randomized trial of letrozole versus clomiphene for infertility in polycystic ovary syndrome, in which researchers reported that hot flushes occurred more commonly in the clomiphene group, while fatigue and dizziness occurred more commonly in the letrozole group (PMID 25006718). That trial recorded these complaints prospectively alongside its primary reproductive outcomes, which is why it is often the anchor reference for symptom-level tolerability rather than a narrative summary.
A separate randomized controlled trial compared stair-step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome and was designed to assess both efficacy and safety of the two escalating-protocol approaches (PMID 37520487). Studies of this design matter for safety interpretation because protocol structure — how quickly treatment is escalated and how long exposure continues — shapes which adverse events are captured at all.
A randomized clinical trial published in JAMA evaluated acupuncture and clomiphene in Chinese women with polycystic ovary syndrome and included adverse-event reporting among its trial outcomes (PMID 28655015). The study illustrates a recurring feature of this literature: clomiphene frequently appears as an active comparator, and its tolerability data are therefore collected as a secondary consideration inside trials designed to answer a different primary question.
Endometrial effects
Because clomiphene acts at estrogen receptors, investigators have looked at the endometrium specifically rather than relying on patient-reported symptoms. A randomized controlled trial examined the effects of clomiphene citrate plus estradiol or progesterone on endometrial ultrastructure, using tissue-level assessment rather than symptom questionnaires (PMID 32309769). This is a different category of finding from a side effect a participant notices, and the two should not be conflated when reading the literature.
Pregnancy and multiple-gestation outcomes
Reproductive trials treat pregnancy outcomes as efficacy endpoints and as safety endpoints simultaneously. In the letrozole-versus-clomiphene trial, researchers reported multiple gestation among the outcomes tracked in both arms and stated that rates of congenital anomalies and pregnancy loss did not differ significantly between the two treatments (PMID 25006718). A 2020 evidence-based guideline on treatments for couples with unexplained infertility reviewed oral agents used in this setting and framed treatment selection around the balance of effectiveness and risk described in the published evidence (PMID 32106976).
Reported Adverse Events in Men Studied Off-Label: What Studies Report
Two systematic reviews with meta-analysis form the backbone of the male literature. A 2023 systematic review and meta-analysis of clomiphene citrate for male infertility pooled hormonal and semen outcomes from the available studies and reported increases in serum testosterone alongside changes in semen parameters, with adverse events reported infrequently across the included trials (PMID 36680549). A 2022 systematic review and meta-analysis of clomiphene citrate for men with hypogonadism similarly reported increases in total testosterone and characterised the tolerability of the included studies as generally favourable (PMID 34933414).
Two caveats about those pooled figures are worth stating plainly. First, meta-analyses can only summarise what the primary studies measured; if the original trials did not systematically ask about visual symptoms, mood change or gynaecomastia, those events cannot appear in the pooled result. Second, both reviews aggregated studies of limited size and duration, and the authors of the 2023 male-infertility review discussed the methodological limitations of the underlying evidence when interpreting the pooled estimates (PMID 36680549).
Enclomiphene and clomiphene comparisons
Clomiphene citrate is a mixture of two isomers, and a 2024 review addressed the safety and efficacy of enclomiphene and clomiphene in hypogonadal men, comparing the evidence available for each (PMID 39434750). Readers interested in whether the two compounds differ in tolerability will find that this review is the paper in the verified set that discusses both agents side by side; it does not, however, replace head-to-head randomized data where such data are limited (PMID 39434750).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow safety was measured across studies
The table below summarises the population and the safety-relevant content of each paper cited on this page. It is a map of the evidence, not a ranking of risk.
| Paper | Population studied | Safety-relevant content reported |
|---|---|---|
| Letrozole vs clomiphene in PCOS, 2014 | Women with PCOS and infertility | Researchers reported hot flushes more often with clomiphene and fatigue and dizziness more often with letrozole, with no significant difference in congenital anomalies or pregnancy loss (PMID 25006718) |
| Stair-step protocol RCT, 2023 | Women with PCOS undergoing ovulation induction | The study compared efficacy and safety of stair-step clomiphene and letrozole protocols (PMID 37520487) |
| Endometrial ultrastructure RCT, 2020 | Women receiving clomiphene with estradiol or progesterone | The trial assessed endometrial ultrastructure as the outcome of interest (PMID 32309769) |
| Acupuncture and clomiphene RCT, 2017 | Chinese women with PCOS | Researchers reported reproductive outcomes and adverse events in a randomized design including clomiphene arms (PMID 28655015) |
| Male infertility meta-analysis, 2023 | Men with infertility | Researchers reported testosterone and semen parameter changes with infrequently reported adverse events (PMID 36680549) |
| Hypogonadism meta-analysis, 2022 | Men with hypogonadism | Researchers reported increases in total testosterone and generally favourable tolerability across pooled studies (PMID 34933414) |
| Enclomiphene and clomiphene review, 2024 | Hypogonadal men | The review examined safety and efficacy of both agents (PMID 39434750) |
Non-prescribed and unsupervised use described in the literature
Part of the published record deals with clomiphene used outside clinical supervision. A 2019 study of anabolic steroid users' misuse of non-traditional prescription drugs reported that people using anabolic androgenic steroids also obtained and used prescription agents outside medical oversight, a pattern the authors documented through user-reported data (PMID 31303195). A clinical practice review on the diagnosis and management of anabolic androgenic steroid use described the clinical problems encountered in this population and the management considerations clinicians face (PMID 30753550).
These papers are relevant to a safety page for a structural reason: adverse events occurring during unsupervised use are rarely captured in trials, so the tolerability estimates from meta-analyses of supervised study populations may not describe unsupervised contexts. Neither cited paper endorses non-prescribed use, and neither provides protocols (PMID 30753550).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appOther contexts where clomiphene has been discussed
Clomiphene has also been raised outside reproductive medicine. A 2020 review of pharmacotherapy for cluster headache discussed clomiphene among agents that have been considered in that condition, placing it within an emerging rather than established evidence base (PMID 31997136). Separately, a review of alternative, plant-based approaches to polycystic ovary syndrome examined the pre-clinical and clinical basis for such agents in a condition where clomiphene is a conventional comparator (PMID 38725974).
What the published studies do not establish
Several limitations recur across the papers cited here, and readers evaluating clomiphene safety claims encountered elsewhere may find them useful:
- Outcome selection drives reported rates. Symptom-level side effects appear only when trials ask about them; the letrozole comparison trial reported hot flushes, fatigue and dizziness because those were among the events it collected (PMID 25006718).
- Pooled tolerability reflects short, supervised exposure. The male meta-analyses summarised studies of limited duration and size (PMID 36680549, PMID 34933414).
- Isomer-level questions remain comparative reviews rather than head-to-head trials. The 2024 review assessed enclomiphene and clomiphene from the existing literature (PMID 39434750).
- Tissue-level findings are not the same as symptoms. Endometrial ultrastructure was an investigational endpoint, not a patient-reported complaint (PMID 32309769).
- Guideline documents weigh effectiveness and risk together, as the 2020 unexplained-infertility guideline did when reviewing oral agents (PMID 32106976).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeEducational context
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medication, a diagnosis or a symptom. Nothing here describes a protocol, a schedule or a course of treatment, and no dose is reproduced that the cited papers do not support.
For readers who want the underlying pharmacology, trial design concepts and how selective estrogen receptor modulators were studied over time, the PeptideU clomiphene course at /learn/clomiphene/ covers that teaching material. This page is deliberately narrower: it catalogues what published trials and reviews reported about adverse events and safety endpoints, so the two resources complement rather than duplicate each other.
References
- Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (The New England Journal of Medicine, 2014)
- Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial (Journal of Medicine and Life, 2023)
- Effects of clomiphene citrate plus estradiol or progesterone on endometrial ultrastructure: An RCT (International Journal of Reproductive Biomedicine, 2020)
- Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial (JAMA, 2017)
- Clomiphene citrate for male infertility: A systematic review and meta-analysis (Andrology, 2023)
- Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis (Andrology, 2022)
- Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
- Evidence-based treatments for couples with unexplained infertility: a guideline (Fertility and Sterility, 2020)
- Diagnosis and Management of Anabolic Androgenic Steroid Use (The Journal of Clinical Endocrinology and Metabolism, 2019)
- Anabolic steroid users' misuse of non-traditional prescription drugs (Research in Social & Administrative Pharmacy, 2019)
- Pharmacotherapy for Cluster Headache (CNS Drugs, 2020)
- Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs (Frontiers in Endocrinology, 2023)
Frequently asked questions
Which adverse events did trials in women report most often?▾
In the randomized comparison of letrozole and clomiphene for infertility in polycystic ovary syndrome, researchers reported that hot flushes occurred more commonly in the clomiphene group, while fatigue and dizziness occurred more commonly in the letrozole group (PMID 25006718). The same trial reported no significant difference between treatments in congenital anomalies or pregnancy loss (PMID 25006718).
What did meta-analyses report about tolerability in men?▾
A 2023 systematic review and meta-analysis of clomiphene citrate for male infertility reported testosterone and semen parameter changes with adverse events reported infrequently across included studies (PMID 36680549). A 2022 systematic review and meta-analysis in men with hypogonadism reported increases in total testosterone and described tolerability across the pooled studies as generally favourable (PMID 34933414).
Has anyone compared clomiphene and enclomiphene for safety?▾
A 2024 review examined the safety and efficacy of enclomiphene and clomiphene in hypogonadal men, discussing both isomer-based options within the available published evidence (PMID 39434750). It is a review rather than a head-to-head randomized trial, so readers should treat its conclusions as a synthesis of existing data rather than direct comparative trial results (PMID 39434750).
Did any study look at effects on the endometrium?▾
Yes. A randomized controlled trial assessed the effects of clomiphene citrate plus estradiol or progesterone on endometrial ultrastructure, using tissue-level examination as the study endpoint (PMID 32309769). That is a laboratory-measured outcome rather than a symptom a participant would notice, so it belongs in a separate category from reported side effects such as hot flushes (PMID 25006718).
Why is unsupervised use discussed on a safety page?▾
Because trial-derived tolerability data come from supervised settings. A 2019 study reported that anabolic androgenic steroid users also obtained and used prescription drugs outside medical oversight (PMID 31303195), and a clinical review described the management challenges clinicians encounter in that population (PMID 30753550). Events in unsupervised contexts are rarely captured by the trials that generate published adverse-event rates.
Is clomiphene studied outside fertility medicine?▾
A 2020 review of pharmacotherapy for cluster headache discussed clomiphene among agents considered in that condition, positioning it within an emerging rather than established evidence base (PMID 31997136). Separately, a review of plant-based approaches to polycystic ovary syndrome examined pre-clinical and clinical evidence in a condition where clomiphene serves as a conventional comparator (PMID 38725974).
What do guidelines say about weighing clomiphene's risks?▾
A 2020 evidence-based guideline on treatments for couples with unexplained infertility reviewed oral agents used in this setting and framed treatment choices around the balance of effectiveness and risk described in the published literature (PMID 32106976). This page is educational only and is not medical advice; decisions about any medication belong with a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.